Lilly’s Trulicity Significantly Cuts Heart Risks in Diabetics

Eli Lilly & Co.’s Trulicity significantly reduced the risk of new or recurring heart complications in people with type 2 diabetes, a key advantage in the increasingly competitive market for drugs to lower blood-sugar levels.

The company plans to present the findings at the American Diabetes Association’s annual meeting in June and offered no further details.

Key Insights

While similar drugs from Novo Nordisk A/S and others also have been shown to reduce the risk of heart attacks, strokes and death, Trulicity is the first to show a benefit in a group made up mainly of people without heart disease. ...